Bristol-Myers Squibb

Explore the latest insights on Bristol-Myers Squibb and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Bristol-Myers Squibb’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Drug

EMA’s CHMP Backs Flexible Dosing for Regeneron’s Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications

Regeneron Pharmaceuticals (NASDAQ: REGN) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of an alternative…

October 19, 2026

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program

October 19, 2026

$EMA's CHMP Backs Indication Extension for Johnson & Johnson's TALVEY – Talquetamab Combination Moves Toward Earlier‑Line Relapsed/Refractory Multiple Myeloma$

EMA’s CHMP Backs Indication Extension for Johnson & Johnson’s TALVEY – Talquetamab Combination Moves Toward Earlier‑Line Relapsed/Refractory Multiple Myeloma

October 19, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company

Bristol-Myers Squibb

EMA’s CHMP Backs Flexible Dosing for Regeneron’s Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program

EMA’s CHMP Backs Indication Extension for Johnson & Johnson’s TALVEY – Talquetamab Combination Moves Toward Earlier‑Line Relapsed/Refractory Multiple Myeloma

Empowering Chinese Pharma’s Global Expansion

LianBio to Wind Down Operations Amid Market Challenges, Announces Special Dividend

BMS Sees Mixed Results in 2023: Growth in New Products Offset by Loss of Exclusivity

Bristol Myers Squibb’s Subcutaneous Opdivo Shows Noninferiority in Phase III ccRCC Trial

BMS’s Opdivo-Yervoy Combo Cuts Cancer Progression Risk by 79% in Phase III Study

BMS’s Mavacamten Used to Treat First Patient with Hypertrophic Cardiomyopathy in Hainan

International Society for Cell & Gene Therapy Comments on FDA’s CAR-T Investigation

BMS’s Abraxane Approved in China for First-Line Metastatic Pancreatic Cancer Treatment

BMS’s Sotyktu, First TYK2 Inhibitor, Hits Chinese Market

About Company